Get the Stockscreener App
2.68
4.28%
0.11
After Hours:
2.65
-0.03
-1.12%
Edesa Biotech Inc stock is traded at $2.68, with a volume of 31,495.
It is up +4.28% in the last 24 hours and down -37.09% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
See More
Previous Close:
$2.57
Open:
$2.53
24h Volume:
31,495
Relative Volume:
1.66
Market Cap:
$8.18M
Revenue:
-
Net Income/Loss:
$-7.72M
P/E Ratio:
-1.0635
EPS:
-2.52
Net Cash Flow:
$-6.25M
1W Performance:
-19.52%
1M Performance:
-37.09%
6M Performance:
-42.15%
1Y Performance:
-24.29%
1-Day Range:
$2.405
$2.68
1-Week Range:
$2.405
$3.7032
52-Week Range:
$2.405
$6.46
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Edesa Biotech Inc Stock (EDSA) Latest News
Edesa Leaps as CEO Boosts Holdings - Baystreet.ca
Edesa Biotech CEO invests $5 million in company By Investing.com - Investing.com India
Edesa Biotech’s Founder Makes Strategic Investment in the Company - GlobeNewswire
Edesa Biotech to Present at Global Conferences - Nasdaq
Edesa Biotech Announces Upcoming Conference Schedule - GlobeNewswire
Edesa Biotech Partners with Wainwright for Share Sales - TipRanks
Edesa Biotech (EDSA) Price Target Increased by 528.00% to 53.38 - MSN
Why Is Infectious Disease Player Edesa Biotech Stock Soaring Today? - MSN
Edesa Biotech (NASDAQ:EDSA) Shares Down 1.6% - Defense World
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. - GlobeNewswire Inc.
S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail
1 Dividend Stock to Invest in the Domestic Steel Market Now - The Globe and Mail
Celsius Holdings Inc (CELH-Q) QuotePress Release - The Globe and Mail
Mackenzie Investments Announces Results of Special Meetings on Mutual Fund and ETF Mergers - Yahoo Canada Finance
ECB interest rate cut likely as Eurozone economy weaker than expected - Yahoo Finance UK
Veradigm Named as the Top Vendor for End-to-End Revenue Cycle Management Solutions - Yahoo Finance UK
Santander starts $1.7 billion share buyback programme - Yahoo Finance UK
FY2024 Earnings Estimate for Edesa Biotech, Inc. (NASDAQ:EDSA) Issued By HC Wainwright - Defense World
H.C. Wainwright bullish on Edesa Biotech stock amid BARDA study support - Investing.com
Edesa Biotech’s (EDSA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
500: Something went wrong - Investing.com UK
EDSA: EB05 Selected for BARDA-Funded Study in ARDS… - Zacks Small Cap Research
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results - GlobeNewswire
Edesa Biotech (NASDAQ:EDSA) Stock Price Down 2% - Defense World
Edesa Biotech Inc expected to post a loss of 58 cents a shareEarnings Preview - XM
Ethiopian Airlines posts 14% jump in full-year revenue - Yahoo Finance UK
Alexis Shamess | Corporate/Commercial Lawyer in Toronto | People - Fasken
Myroslav Chwaluk | Mergers & Acquisitions Lawyer in Toronto | People - Fasken
A. Wojtek BaraniakPolish-speaking Corporate/Commercial lawyer in Toronto | People - Fasken
MoneySmart’s June Lucky Draw 2024 - Yahoo Finance
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential - Yahoo Finance UK
Homebuilder Vistry boosts output target as cost inflation softens - Yahoo Finance UK
German environmental authorities approve Tesla site expansion - Yahoo Finance UK
Cipher Pharmaceuticals - The Pharma Letter
Edesa Biotech (NASDAQ:EDSA) Receives Buy Rating from HC Wainwright - Defense World
Allied gaming executive Choi buys shares worth $778k By Investing.com - Investing.com
Bioventus exec sells over $14k in company stock By Investing.com - Investing.com
Edesa's Paridiprubart Selected for U.S.-Funded Platform Trial in General ARDS - Contract Pharma
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS - StockTitan
Edesa’s Paridiprubart Selected For U.S.-Funded Platform Trial In General ARDS - Contract Pharma
Comparing Assertio (NASDAQ:ASRT) and Edesa Biotech (NASDAQ:EDSA) - Defense World
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Rises By 32.1% - Defense World
Perritt Capital Management Inc. Has $482000 Stake in Usio, Inc. (NASDAQ:USIO) - Defense World
Anixa Biosciences director buys shares worth over $1,000 By Investing.com - Investing.com
Stephens Inc. AR Has $1.30 Million Stock Holdings in DuPont de Nemours, Inc. (NYSE:DD) - Defense World
French jet engine maker Safran gets Italy's clearance to buy Microtecnica - Yahoo Finance UK
Edesa Biotech Shareholders Approve Board and Compensation PlansTipRanks.com - TipRanks
Edesa Biotech, Inc. Forecasted to Earn FY2024 Earnings of ($1.95) Per Share (NASDAQ:EDSA) - Defense World
FY2024 EPS Estimates for HEICO Co. Lifted by Analyst (NYSE:HEI) - Defense World
EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo - Zacks Small Cap Research
Kiora Pharmaceuticals (KPRX) Stock Forecast and Price Target 2024 - MarketBeat
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):